Dashboard
Manage Tickers

CAPR


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

capricor-therapeutics-q2-2024-gaap-eps-035-beats-036-estimate-sales-3971m-beat-3664m-estimate
Capricor Therapeutics Q2 2024 GAAP EPS $(0...
08/07/2024 20:58:52

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of...

unveiling-6-analyst-insights-on-capricor-therapeutics
Unveiling 6 Analyst Insights On Capricor T...
07/02/2024 12:01:01

hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Capr...
07/02/2024 10:40:56

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

capricor-therapeutics-to-join-russell-2000-and-russell-3000-indexes
Capricor Therapeutics To Join Russell 2000...
07/01/2024 13:11:43

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...

whats-going-on-with-capricor-therapeutics-stock-friday
What's Going On With Capricor Therapeutics...
06/28/2024 16:58:19

The biotechnology company said deramiocel increased cardiac function based on several different measures.

capricor-therapeutics-announces-long-term-benefit-of-deramiocel-in-both-skeletal-muscle-and-cardiac-function-in-the-hope-2-ole-study-in-duchenne-muscular-dystrophy
Capricor Therapeutics Announces Long-Term ...
06/28/2024 13:02:32

-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patient...

capricor-therapeutics-announces-the-fda-has-scheduled-pre-bla-meeting-with-the-company-for-the-treatment-of-duchenne-muscular-dystrophy
Capricor Therapeutics Announces The FDA Ha...
06/25/2024 12:37:48

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...

capricor-therapeutics-files-for-mixed-shelf-offering-of-up-to-150m
Capricor Therapeutics Files For Mixed Shel...
06/14/2024 20:34:05

-SEC Filing

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
06/11/2024 20:31:35

whats-going-on-with-capricor-therapeutics-stock-tuesday
What's Going On With Capricor Therapeutics...
06/11/2024 19:27:37

Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA).

capricor-therapeutics-completes-type-b-meeting-with-fda-for-cap-1002-program-for-duchenne-muscular-dystrophy-with-aim-to-expedite-bla-pathway
Capricor Therapeutics Completes Type-B Mee...
06/11/2024 13:31:19

--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--

whats-going-on-with-capricor-therapeutics-stock-tuesday
What's Going On With Capricor Therapeutics...
06/04/2024 17:12:51

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the on...

capricor-therapeutics-reports-3-year-efficacy-results-from-hope-2-open-label-extension-study-of-cap-1002-in-dmd
Capricor Therapeutics Reports 3-Year Effic...
06/04/2024 13:05:39

--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP...

oppenheimer-initiates-coverage-on-capricor-therapeutics-with-outperform-rating-announces-price-target-of-14
Oppenheimer Initiates Coverage On Capricor...
05/17/2024 09:37:55

Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Outperform rating and a...

expert-ratings-for-capricor-therapeutics
Expert Ratings For Capricor Therapeutics
05/14/2024 19:01:00

ladenburg-thalmann-maintains-buy-on-capricor-therapeutics-raises-price-target-to-25
Ladenburg Thalmann Maintains Buy on Capric...
05/14/2024 18:23:48

Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price targ...

cantor-fitzgerald-reiterates-overweight-on-capricor-therapeutics-maintains-8-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/14/2024 12:58:47

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Overweight and maintains $8 p...

hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Capr...
05/14/2024 11:31:35

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

capricor-therapeutics-expects-available-cash--equivalents-to-be-sufficient-to-cover-anticipated-expenses-and-capital-requirements-into-q1-of-2025
Capricor Therapeutics Expects Available Ca...
05/13/2024 20:20:40

capricor-therapeutics-q1-2024-gaap-eps-031-misses-011-estimate-sales-4906m-miss-9700m-estimate
Capricor Therapeutics Q1 2024 GAAP EPS $(0...
05/13/2024 20:16:14

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION